Raymond James Financial Inc. Purchases Shares of 54,783 Tyra Biosciences, Inc. (NASDAQ:TYRA)

Raymond James Financial Inc. acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, Holdings Channel.com reports. The fund acquired 54,783 shares of the company’s stock, valued at approximately $761,000.

A number of other hedge funds have also modified their holdings of the stock. Alta Partners Management Company L.P. purchased a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $56,716,000. Janus Henderson Group PLC acquired a new stake in shares of Tyra Biosciences during the third quarter worth approximately $24,994,000. Victory Capital Management Inc. boosted its holdings in shares of Tyra Biosciences by 88.3% during the fourth quarter. Victory Capital Management Inc. now owns 56,640 shares of the company’s stock worth $787,000 after purchasing an additional 26,560 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Tyra Biosciences during the 3rd quarter valued at $593,000. Finally, Barclays PLC boosted its position in Tyra Biosciences by 200.5% during the third quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after purchasing an additional 25,106 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Trading Down 6.7 %

NASDAQ TYRA opened at $7.74 on Friday. Tyra Biosciences, Inc. has a 1 year low of $7.52 and a 1 year high of $29.60. The company has a fifty day simple moving average of $11.72 and a 200 day simple moving average of $15.90. The company has a market cap of $410.92 million, a P/E ratio of -4.81 and a beta of 1.19.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 21,998 shares of company stock worth $344,818 over the last three months. 15.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TYRA has been the subject of a number of recent research reports. UBS Group assumed coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.